M&A / Deals EverSea Medicines to acquire Hasten Biopharmaceuticals Pharmaceutical Business ReviewThe acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. M&A / DealsRead full story Post navigation Previous: Jeito Capital secures over $1.2bn for new biopharma investmentsNext: 23andMe study explains variable results with obesity drugs Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026